The use of the osteoporosis drug denosumab (Prolia) to prevent fractures associated with advanced chronic kidney disease (CKD) in patients on kidney dialysis significantly increases the risk for ...
The US Food and Drug Administration (FDA) has added a boxed warning to the label of the osteoporosis drug denosumab (Prolia) about increased risk for severe hypocalcemia in patients with advanced ...
FDA’s boxed warning on denosumab follows study results showing increased and early risks of severe hypocalcemia in patients on dialysis. The Food and Drug Administration (FDA) has added a new boxed ...
A new study conducted across five U.K. air ambulance services has revealed significant variation in calcium levels among trauma patients receiving pre-hospital blood transfusions—highlighting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results